9-valent HPV vaccine

also known as 9vHPV · 9vHPV vaccine · Cecolin 9 · Gardasil 9

Developed for: human papilloma virus infection · adenocarcinoma in situ · anogenital human papillomavirus infection · cervical cancer · cervical intraepithelial neoplasia grade 2/3 · vaginal cancer · vulva cancer · cervical intraepithelial neoplasia
Investigated by: Cancer Prevention Research Institute of Texas · Chongqing Bovax Biopharmaceutical Co., Ltd. · Shanghai Bovax Biotechnology Co., Ltd. · The University of Texas Medical Branch, Galveston · Augusta University · Talia Sainz Costa
+3 more
· Universitaire Ziekenhuizen KU Leuven · Yale University · Zhejiang Provincial Center for Disease Control and Prevention

Trials 9

today NCT07281677 · Ph 4 NCT05439083 · Ph 4 NCT05672927 · Ph 4 NCT04895020 · Ph 3 NCT04425291 · Ph 3 NCT04311528 · Ph 4 NCT03943875 · Ph 4 NCT03525210 · Ph 3 NCT02864147 · Ph 2

2017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 21 trial · 1 missed
Phase 2	NCT02864147	Jul 2016 → May 2022	cervical intraepithelial neoplasia	Yale University	Completed	Missed primary
Phase 33 trials
Phase 3	NCT04895020	May 2021 → Jan 2023	adenocarcinoma in situ, anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia grade 2/3 +2	Shanghai Bovax Biotechnology Co., Ltd.	Unknown	No outcome recorded
Phase 3	NCT04425291	May 2020 → Sep 2021	adenocarcinoma in situ, anogenital human papillomavirus infection, cervical cancer, cervical intraepithelial neoplasia grade 2/3 +2	Shanghai Bovax Biotechnology Co., Ltd.	Completed	No outcome recorded
Phase 3	NCT03525210	Apr 2018 → Sep 2019	HIV infectious disease, human papilloma virus infection	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 45 trials
Phase 4	NCT07281677	Dec 2025 → Dec 2028 expected	human papilloma virus infection	Zhejiang Provincial Center for Disease Control and Prevention	Active not recruiting	No outcome recorded
Phase 4	NCT05439083	Mar 2023 → Sep 2024	human papilloma virus infection	Talia Sainz Costa	Unknown	No outcome recorded
Phase 4	NCT05672927	Jan 2023 → Aug 2026 overdue	human papilloma virus infection	The University of Texas Medical Branch, Galveston	Recruiting	No outcome recorded
Phase 4	NCT04311528	Apr 2020 → Dec 2021	human papilloma virus infection	Augusta University	Unknown	No outcome recorded
Phase 4	NCT03943875	Jun 2019 → Jan 2025	human papilloma virus infection	The University of Texas Medical Branch, Galveston	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2015-02-26	Merck Sharp & Dohme LLC	Merck’s 9-Valent HPV Vaccine, GARDASIL®9, Recommended by CDC’s Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21 merck.com ↗

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 10 sources stand behind the page.

Field	Value	Cited text
Known as	9-valent HPV vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02864147 ↗ 8 NCT04895020 ↗ NCT04425291 ↗ NCT03943875 ↗ NCT07281677 ↗ NCT03525210 ↗ NCT05672927 ↗ NCT04311528 ↗ NCT05439083 ↗
Known as	9vHPV	“The nonavalent HPV vaccine (9vHPV) provides protection against 9 high-risk HPV serotypes” NCT05439083 ↗
Known as	9vHPV vaccine	“a 9-valent human papillomavirus (9vHPV) vaccine (HPV-6/11/16/18/31/33/45/52/58) is recommended” PMID 38320488 ↗ Jan 2024
Known as	Cecolin 9	“9vhpv\[Cecolin 9\]- 9vhpv\[Cecolin 9\]” NCT07281677 ↗
Known as	Gardasil 9	“9vhpv\[Gardasil 9\]-9vhpv\[Gardasil 9\]” NCT07281677 ↗
Modality	Vaccine	“9-valent HPV vaccine” NCT02864147 ↗
Route	Intramuscular	“0.5 mL intramuscular injection of 9vHPV” NCT05439083 ↗